United Kingdom· GB-APID-31191311000001100
Nucala 100mg powder for solution for injection vials
A mepolizumab product containing mepolizumab, registered in United Kingdom by GlaxoSmithKline UK Ltd. The same ATC class is registered in 2 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Mepolizumab is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AC06 (mepolizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 1 of them publish a price we can compare per daily dose
Mepolizumab · ATC L04AC06
2 / 19 countries
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Mepolizumab
- Manufacturer
- GlaxoSmithKline UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AC06
- ATC class
- Mepolizumab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5000123114672
- gtin05054290003253
- gtin05000123115457
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mepolizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUCALAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumNucala 100 mgGlaxoSmithKline Trading Services
- SpainNUCALA 100 MG POLVO PARA SOLUCION INYECTABLEGlaxosmithkline Trading Services Limited
- IcelandNucalaGlaxoSmithKline Trading Services Limited
- PolandNucalaGlaxoSmithKline Trading Services Limited
- SwedenNucala 100 mg Pulver till injektionsvätska, lösningGlaxoSmithKline Trading Services Ltd
- ItalyNUCALA*1 flaconcino SC 100 mgGLAXOSMITHKLINE TRAD.SERV.LTD
- FinlandNucalaGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nucala
- Liechtenstein · Nucala
- Norway · Nucala
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/adcc75f7-6f2e-45aa-9da4-91653bb639c2 GET /v1/drugs/adcc75f7-6f2e-45aa-9da4-91653bb639c2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "31191311000001100",
"desc": "Nucala 100mg powder for solution for injection vials (GlaxoSmithKline UK Ltd)",
"form": "Powder for solution for injection",
"vpid": "31210311000001108",
"source": "dmd",
"vtm_id": "781309006",
"strength": "100 mg",
"substance": "Mepolizumab",
"ingredient": "Mepolizumab",
"supplier_code": "4012301000001105"
}See everything about mepolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.